Scopus Biopharma Inc. (SCPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCPS Stock Price Chart Interactive Chart >
SCPS Price/Volume Stats
|Current price||$0.13||52-week high||$1.25|
|Prev. close||$0.10||52-week low||$0.06|
|Day high||$0.13||Avg. volume||39,312|
|50-day MA||$0.15||Dividend yield||N/A|
|200-day MA||$0.32||Market Cap||2.74M|
Scopus Biopharma Inc. (SCPS) Company Bio
Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.
Most Popular Stories View All
SCPS Latest News Stream
|Loading, please wait...|
SCPS Latest Social Stream
View Full SCPS Social Stream
Latest SCPS News From Around the Web
Below are the latest news stories about SCOPUS BIOPHARMA INC that investors may wish to consider to help them evaluate SCPS as an investment opportunity.
We're starting off the final trading day this week with a look at the biggest pre-market stock movers to watch for Friday!
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!
It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday!
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 8-12, 2022 at the Boston C
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Positioned to Go Public in 2023 NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, a
SCPS Price Returns